echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > More than 10 new deals in November! Involving Sanofi, Henlius, Simcere Pharmaceutical, Biocytogen, etc

    More than 10 new deals in November! Involving Sanofi, Henlius, Simcere Pharmaceutical, Biocytogen, etc

    • Last Update: 2023-01-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    In November 2022, the activity of licensing in and outside of local enterprises and between domestic enterprises recovered
    compared with October.
    According to GBI The SOURCE database global trading section, a total of the following 12 related transactions, mainly covering oncology, cardiovascular system, nervous system and other fields
    .

    GBI SOURCE Global Trading

    Table 1.
    November 2022 license to introduce transactions

    Table 2.
    Licensing transactions in November 2022

    Table 3.
    Local licensing transaction in November 2022

    Source: GBI SOURCE Global Trading Section

    GBI SOURCE

    Licensing Introduction Transactions

    Licensing Introduction Transactions

    License-in

    Buchang Pharmaceuticals and Remet reached a development and licensing agreement for the REMD-290 related project

    Buchang Pharmaceuticals and Remet reached a development and licensing agreement for the REMD-290 related project

    ■ Licensor: Rimet

    Licensor:

    ■ Licensee: Buchang Pharmaceutical

    Licensee:

    ■ Product/Technology: REMD-290

    Product/Technology:

    Sichuan Luzhou Buchang Biopharmaceutical Co.
    , Ltd.
    , a subsidiary of Buchang Pharmaceutical, signed a cooperative development and licensing agreement
    with Ruimide Biomedical Technology Co.
    , Ltd.
    of the United States.
    Ruimed granted Luzhou Buchang an exclusive license to REMD-290 patent in Chinese mainland and Russia, and Luzhou Buchang selected two bispecific antibody molecules, BC921 and BC922, derivatives of REMD-290 monoclonal antibody, to conduct process research and development, development and commercialization
    of the licensed product in the target region.
    Luzhou will pay a total of US$14.
    2 million in milestone payments, as well as a percentage of the sales commission
    .
    The parties also agreed in detail on the cost of development, registration and clinical research of the licensed products
    .

    REMD-290

    Simcere Pharmaceuticals received US$50 million authorization from Daridorexant, a new insomnia drug from Idosia in Switzerland

    Simcere Pharmaceuticals received US$50 million authorization from Daridorexant, a new insomnia drug from Idosia in Switzerland

    ■ Licensor: Idorsia Pharmaceuticals Ltd

    Licensor:

    ■ Licensee: Simcere Pharmaceutical

    Licensee:

    ■ Product/Technology: Daridorexant

    Product/Technology:

    Simcere Pharmaceuticals announced a partnership with Swiss biopharmaceutical company Idorsia Ltd.
    enters into an exclusive license agreement
    .
    Simcere Pharmaceutical has obtained the exclusive rights to develop and commercialize Daridorexant, Idorsia's new anti-insomnia drug, in Greater China (Chinese mainland, Hong Kong and Macau), and will be responsible for the clinical research and development
    of the project in China.
    Idosia will receive a $30 million down payment and will be eligible for an additional $20 million milestone payment upon approval of the China registration, as well as a low double-digit tiered royalty
    based on future sales.
    Daridorexant's ability to improve both nighttime sleep and daytime function in adults with chronic insomnia disorder was approved
    in the United States and Europe in January and April 2022.

    Daridorexant

    Tenacia acquires exclusive rights in Greater China, a ganaxolone owned by Marinus

    Tenacia acquires exclusive rights in Greater China, a ganaxolone owned by Marinus

    ■ Licensor: Marinus Pharmaceuticals, Inc.

    Licensor:

    ■ Licensee: Tenacia Biotechnology

    Licensee:

    ■ Product/Technology: Ganaxolone

    Product/Technology:

    U.
    S.
    pharmaceutical company Marinus Pharmaceuticals Inc.
    and Chinese company Tenacia Biotechnology (Shanghai) Co.
    , Ltd.
    signed a cooperation and supply agreement
    .
    Tenacia will acquire exclusive rights
    to develop and commercialize the oral and intravenous formulations of ganaxolone by Marinus in Chinese mainland, Hong Kong, Macau and Taiwan.
    Tenacia also has the right to prioritize
    negotiations for any future next-generation formulation or prodrug.
    Marinus will receive $10 million upfront, up to $256 million in administrative, development and sales milestone payments, and low-double-digit tiered royalties
    based on future net sales.
    Tenacia will be responsible for developing the drug in China for the treatment of CDKL5 deficiency, tuberous sclerosis syndrome and status epilepticus, and will also work with Marinus to develop a new generation of ganaxolone formulations
    .

    ganaxolone

    Yuer Pharma acquired the rights to Aclaris' novel JAK1/3 inhibitor, ATI-1777, in Greater China

    Yuer Pharma acquired the rights to Aclaris' novel JAK1/3 inhibitor, ATI-1777, in Greater China

    ■ Licensor: Aclaris Therapeutics, Inc.

    Licensor:

    ■ Licensee: Yuer Pharmaceutical

    Licensee:

    ■ Product/Technology: ATI-1777

    Product/Technology:

    American company Aclaris Therapeutics, Inc.
    entered into an exclusive license agreement
    with Yuer Pharmaceutical.
    Yuer Pharma has acquired the rights
    to develop, manufacture and commercialize ATI-1777 for all indications, including but not limited to atopic dermatitis, in Greater China (Chinese mainland, Hong Kong, Macau and Taiwan).
    Under the agreement, Aclaris will receive an upfront payment of $5 million, up to $91 million in administrative oversight and sales milestone payments, and royalties
    based on future sales.

    ATI-1777

    Luca obtains the mainland commercialization rights of Cambridge Cognition's neuropathy assessment tool

    Luca obtains the mainland commercialization rights of Cambridge Cognition's neuropathy assessment tool

    ■ Licensor: Cambridge Cognition

    Licensor:

    ■ Licensee: Luca Healthcare

    Licensee:

    ■ Product/Technology: Not announced

    Product/Technology:

    Luca Healthcare announced that it has partnered with British company Cambridge Cognition signed a 10-year licensing agreement
    .
    Under the agreement, Luca will get Cambridge Cognition's cognitive assessment system is licensed
    to commercialize in the Chinese mainland market.
    The collaboration includes the CATALAB cognitive testing system, which enables sensitive and objective measures of cognitive function, including working memory, learning, executive function, vision, speech and episodic memory
    .
    These tests, available in multiple languages and include Chinese, can be used to detect early symptoms
    of neurodegenerative diseases such as dementia.

    Licensing transactions

    Licensing transactions

    License-out

    Sanofi joins hands with Insilico to advance AI pharmaceuticals

    Sanofi joins hands with Insilico to advance AI pharmaceuticals

    ■ Licensor: Insilico

    Licensor:

    ■ Licensee: Sanofi

    Licensee:

    ■ Product/Technology: Pharma.
    AI drug discovery platform

    Product/Technology:

    Insilico announces a multi-year strategic research collaboration
    with Sanofi for multiple targets.
    The collaboration will leverage Insilico's artificial intelligence (AI)-driven Pharma.
    AI drug discovery platform to advance drug candidate development based on no more than six innovative targets
    .
    Sanofi will pay Insilico's aggregate upfront payment and target nomination fees of up to US$21.
    5 million, supported by Insilico's Pharma.
    AI platform and interdisciplinary team of drug discovery scientists to identify, synthesize and advance research on high-quality lead compounds to clinical development
    candidates.
    If the collaboration reaches key R&D and commercial milestones, Insilico will also receive additional milestone payments, totaling up to $1.
    2 billion.

    The collaboration will also provide phased royalties
    ranging from medium to low double digits for the commercialization of successfully developed products.

    Pharma.
    AI drug discovery platform

    Harbour Biopharma granted Moderna only heavy chain antibody discovery platform and derivative sequence rights for $506 million

    Harbour Biopharma granted Moderna only heavy chain antibody discovery platform and derivative sequence rights for $506 million

    ■ Licensor: Harbour Pharmaceutical

    Licensor:

    ■ Licensee: Moderna, Inc.

    Licensee:

    ■ Product/Technology: Heavy chain antibody (HCAb) discovery platform only

    Product/Technology:

    Harbour Biopharma announced that its wholly-owned subsidiary, Nona Biologics (Suzhou) Co.
    , Ltd.
    , has entered into a licensing and partnership agreement
    with Moderna.
    The collaboration will focus on the discovery and development of nucleic acid-based immunotherapies
    using Harbour Biopharma's proprietary heavy-chain antibody (HCAb) discovery platform.
    Nona Biologics shall receive an upfront payment of $6 million and potential milestone payments of up to approximately $500 million and will be eligible to collect tiered royalties from Moderna for each product developed under the Agreement
    .
    In addition, Moderna will be granted an exclusive sublicensable license to develop nucleic acid products
    using a set of sequences derived from Harbour Pharma's HCAb platform for multiple targets.

    Heavy-chain antibody (HCAb) discovery platform only

    Yifan Pharma granted ACROTECH the right to distribute F-627 in the United States

    Yifan Pharma granted ACROTECH the right to distribute F-627 in the United States

    ■ Licensor: Yifan Pharmaceutical

    Licensor:

    ■ Licensee: Acrotech Biopharma Inc.

    Licensee:

    ■ Product/Technology: F-627

    Product/Technology:

    Yifan Pharmaceutical issued an announcement that its holding subsidiary Yiyi licensed the exclusive distribution right of the product Ebegastim α injection (formerly known as recombinant human granulocyte colony-stimulating factor-Fc fusion protein, proposed trade name: Yilishu, R&D code: F-627) in the United States to ACROTECH; ACROTECH pays exclusive license fees (including down payment and milestone payments) up to $236.
    5 million to the United States, as well as double-digit tiered net sales royalties
    .

    Ebegastim α injection

    Biocytogen has entered into an antibody development agreement with ADC Therapeutics

    Biocytogen has entered into an antibody development agreement with ADC Therapeutics

    ■ Licensor: Biocytogen

    Licensor:

    ■ Licensee: ADC Therapeutics SA

    Licensee:

    ■ Product/technology: antibody molecules for 3 tumor targets

    Product/Technology:

    Biocytogen (Beijing) MedTech Co.
    , Ltd.
    announced a partnership with Switzerland-based ADC Therapeutics SA signs an optional antibody drug molecule evaluation and authorization agreement
    .
    Biocytogen licenses ADCs Therapeutics evaluated
    antibody molecules for 3 tumor targets with independent intellectual property rights of Biocytogen.
    ADC after completion of evaluation Therapeutics has the right to license selected antibody molecules for worldwide use in ADC drug development and commercialization; Biocytogen will retain all global benefits
    to these antibody molecules for use other than ADC drugs.
    Biocytogen will receive an upfront payment and, for each licensed molecule, Biocytogen will receive option execution fees, payment for various stages of development and commercialization milestones, accumulating up to tens of millions of dollars; and single-digit net sales share
    .

    Antibody molecules for 3 tumor targets

    Local licensing transactions

    Local licensing transactions

    Jichuan Pharmaceutical and Hengyi Biotechnology cooperated to develop two products

    Jichuan Pharmaceutical and Hengyi Biotechnology cooperated to develop two products

    ■ Licensor: Hengyi Biotechnology

    Licensor:

    ■ Licensee: Jichuan Pharmaceutical

    Licensee:

    ■ Products/technologies: PDE4 inhibitors, protease inhibitors

    Product/Technology:

    Jichuan Pharmaceutical Group Co.
    , Ltd.
    and Hengyi Biopharmaceutical (Shanghai) Co.
    , Ltd.
    reached an exclusive cooperation agreement to cooperate
    in the Chinese mainland (excluding Hong Kong, Macao and Taiwan) for the indications agreed on a PDE4 inhibitor pharmaceutical product (including its various dosage forms) and a combination product (target product 1) and a protease inhibitor pharmaceutical product (including its various dosage forms, target product 2) owned or controlled by Hengyi Biologics 。 The down payment paid by Jichuan Limited will not exceed 180 million RMB, the development milestone payment will not exceed 12.
    125 million US dollars, the sales milestone will not exceed 20 million US dollars, and it will share the subsequent R&D expenses of target products 1 and 2 with Hengyi Biotech in the same proportion, and enjoy the sales profit
    according to the same proportion.
    The existing indications for Target Product 1 are moderate to severe plaque psoriasis and mild to moderate atopic dermatitis, and the existing indication for Target Product 2 is to improve the recovery of intestinal function and reduce postoperative intestinal obstruction
    in patients undergoing selective bowel resection.

    Hansen Pharmaceutical obtained the rights of Pumis EGFR/cMet dual antibody PM1080 in China

    Hansen Pharmaceutical obtained the rights of Pumis EGFR/cMet dual antibody PM1080 in China

    ■ Licensor: Promes Biotechnology

    Licensor:

    ■ Licensee: Hansen Pharmaceutical

    Licensee:

    ■ Product/Technology: PM1080

    Product/Technology:

    Hansen Pharmaceutical announced that it has obtained an exclusive license
    to develop and commercialize Pumis's bispecific antibody PM1080 in China, including Hong Kong, Macau and Taiwan.
    Hansen Pharmaceutical will be responsible for the development, registration approval, manufacturing and commercialization of PM1080 in China, and pay a down payment of RMB 50 million, a commercialization milestone payment of up to RMB 1.
    418 billion, and a tiered royalty
    based on future net sales in China.
    PM1080 is an EGFR/cMet bispecific antibody with great therapeutic potential to simultaneously block the signaling of EGFR and c-Met and inhibit tumor growth and survival, and is currently in the preclinical research stage
    .

    PM1080

    Henlius granted Fosun Pharma Hans-like commercialization rights in the US market

    Henlius granted Fosun Pharma Hans-like commercialization rights in the US market

    ■ Licensor: Henlius

    Licensor:

    ■ Licensee: Fosun Pharma

    Licensee:

    ■ Product/Technology: Serplulimab

    Product/Technology:

    Henlius announced that it has entered into a license agreement with Fosun Pharma Industry, a subsidiary of Fosun Pharma, granting it an exclusive license to
    commercialize Hans-like (serplulimab injection) in the US market.
    Fosun Pharma is required to make an upfront payment of RMB1 billion to Henlius, a one-off regulatory milestone payment of US$50 million (approximately RMB358 million), a maximum of US$650 million (approximately RMB4.
    652 billion) of sales milestone payments, and royalties paid on a pro rata basis based on net sales
    .
    This transaction aims to enhance the accessibility and recognition of Hans-like in overseas markets through Fosun Pharma's mature system in medical affairs and market access
    .

    Hans-like

    Shanghai Medicine introduced the first generic drug of Ambisen carbamazepine sustained-release tablets, and multi-party cooperation ensured supply and marketing

    Shanghai Medicine introduced the first generic drug of Ambisen carbamazepine sustained-release tablets, and multi-party cooperation ensured supply and marketing

    ■ Licensor: Ambisen

    Licensor:

    ■ Licensee: Shangyao Zhongxi

    Licensee:

    ■ Product/Technology: Carbamazepine

    Product/Technology:

    Shanghai Zhongxi Sanwei Pharmaceutical Co.
    , Ltd.
    , Shanghai Ambisen Pharmaceutical Technology Co.
    , Ltd.
    , Qingdao BAHEAL Pharmaceutical Co.
    , Ltd.
    , and Shanghai Pharmaceutical Group Pharmaceutical Sales Co.
    , Ltd.
    reached a multi-party cooperation
    around the first generic drug of carbamazepine sustained-release tablets (II) under Ambisen.
    The generic drug of carbamazepine sustained-release tablets (II) independently developed by Ambisen was first approved by the US FDA in 2021 and sold to the US market; Approved in China in 2022, it is the first imitation in China, and the trade name: Shu Ningping
    .
    In this cooperation, Ambisen transferred the marketing authorization approval of the three specifications of Shuningping held by Shuningping to Shanghai Pharmaceutical Zhongxi
    .
    BAHEAL Pharmaceutical will provide Shuningping with stable quality supply guarantee; Shanghai Medicine Sales will be equipped with a professional sales team in the field of Shuningping indications to carry out sales promotion
    in the domestic market.

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.